{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020966","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.916315+00:00","generated_at":"2026-06-01T09:51:30.517688+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion","bullets":["Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.","First patient dosed in multi-dose portion of Phase I trial, evaluating safety of repeat administrations.","Company intends to advance Decoy20 into combination studies with a checkpoint inhibitor."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020966","json":"https://secwatch.observer/filing/0001493152-24-020966.json","markdown":"https://secwatch.observer/filing/0001493152-24-020966.md","text":"https://secwatch.observer/filing/0001493152-24-020966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224020966/0001493152-24-020966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315224020966/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:51:30.517688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}